Research progress of prognostic evaluation in thymoma

doi:10.3760/cma.j.issn.1673-422X.2019.12.012

Abstract

Abstract: Thymoma is the most common primary malignant tumor which occurs in the anterior mediastinum. The incidence of thymoma is relatively low with scarce large sample and multicenter studies available on the prognostic factors of these patients, and the related indexes for evaluating the prognosis are still under investigation. Looking for possible predictive indicators for prognosis evaluation, we can grasp the initiative of diagnosis, seize the opportunity of treatment, and intervene in the poor prognostic factors, thereby improving the prognosis of patients.

Key words: Thymoma, Prognosis, Thymic epithelial tumors

Zhang Ruiyun, Luo Hui, Duan Yongjian, Ge Hong. Research progress of prognostic evaluation in thymoma[J]. Journal of International Oncology, 2019, 46(12): 764-768.

References ［41］

［1］	Komaki R, Gomez DR. Radiotherapy for thymic carcinoma: adjuvant, inductive, and definitive［J］. Front Oncol, 2014, 3: 330. DOI: 10.3389/fonc.2013.00330.
［2］	Modh A, Rimner A, Allen PK, et al. Treatment modalities and outcomes in patients with advanced invasive thymoma or thymic carcinoma: a retrospective multicenter study［J］. Am J Clin Oncol, 2016, 39(2): 120-125. DOI: 10.1097/coc.0000000000000024.
［3］	Meurgey A, Girard N, Merveilleux du Vignaux C, et al. Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors［J］. J Thorac Oncol, 2017, 12(10): 1571-1581. DOI: 10.1016/j.jtho.2017.06.072.
［4］	Yuan ZY, Gao SG, Mu JW, et al. Long-term outcomes of 307 patients after complete thymoma resection［J］. Chin J Cancer, 2017, 36(1): 46. DOI: 10.1186/s40880-017-0213-8.
［5］	Kocer B, Kaplan T, Gunal N, et al. Longterm survival after R0 resection of thymoma［J］. Asian Cardiovasc Thorac Ann, 2018, 26(6): 461-466. DOI: 10.1177/0218492318778634.
［6］	Tseng YC, Tseng YH, Kao HL, et al. Correction: long term oncological outcome of thymoma and thymic carcinoma-an analysis of 235 cases from a single institution［J］. PLoS One, 2017, 12(9): e0185399. DOI: 10.1371/journal.pone.0185399.
［7］	Liang G, Gu Z, Li Y, et al. Comparison of the Masaoka-Koga staging and the International Association for the Study of Lung Cancer/the International Thymic Malignancies Interest Group proposal for the TNM staging systems based on the Chinese Alliance for Research in Thymomas retrospective database［J］. J Thorac Dis, 2016, 8(4): 727-737. DOI: 10.21037/jtd.2016.03.22.
［8］	Roden AC, Yi ES, Jenkins SM, et al. Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis［J］. Am J Surg Pathol, 2015, 39(4): 427-441. DOI: 10.1097/pas.0000000000000391.
［9］	Safieddine N, Liu G, Cuningham K, et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma［J］. J Thorac Oncol, 2014, 9(7): 1018-1022. DOI: 10.1097/jto.0000000000000215.
［10］	Fukui T, Fukumoto K, Okasaka T, et al. Prognostic impact of tumour size in completely resected thymic epithelial tumours［J］. Eur J Cardiothorac Surg, 2016, 50(6): 1068-1074. DOI: 10.1093/ejcts/ezw178.
［11］	Hwang Y, Park IK, Park S, et al. Lymph node dissection in thymic malignancies: implication of the ITMIG lymph node map, TNM stage classification, and recommendations［J］. J Thorac Oncol, 2016, 11(1): 108-114. DOI: 10.1016/j.jtho.2015.09.001.
［12］	Bian D, Zhou F, Yang W, et al. Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based study［J］. Oncotarget, 2018, 9(15): 12273-12283. DOI: 10.18632/oncotarget.24315.
［13］	Nicholson AG, Detterbeck FC, Marino M, et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors［J］. J Thorac Oncol, 2014, 9(9 Suppl 2): S73-S80. DOI: 10.1097/jto.0000000000000303.
［14］	Zhao M, Yin J, Yang X, et al. Nomogram to predict thymoma prognosis: a population-based study of 1312 cases［J］. Thorac Cancer, 2019, 10(5): 1167-1175. DOI: 10.1111/1759-7714.13059.
［15］	杨适泽, 曲晓翰, 赵海斌, 等. 469例胸腺瘤患者预后因素分析［J］. 中华胸心血管外科杂志, 2015, 31(11): 698-699. DOI: 10.3760/cma.j.issn.10014497.2015.11.016.
［16］	袁东风, 谷志涛, 梁光辉, 等. 胸腺瘤合并重症肌无力患者预后的临床研究［J］. 中国肺癌杂志, 2018, 21(1): 1-7. DOI: 10.3779/j.issn.1009-3419.2018.01.01.
［17］	张云峰, 于磊, 景筠, 等. 合并重症肌无力的胸腺瘤治疗与预后特点分析［J］. 中华外科杂志, 2015, 53(8): 612-616. DOI: 10.3760/cma.j.issn.0529-5815.2015.08.012.
［18］	Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: a propensity score-matched cohort study from the European Society of Thoracic Surgeons Database［J］. J Thorac Cardiovasc Surg, 2016, 151(1): 47-57. e41. DOI: 10.1016/j.jtcvs.2015.08.034.
［19］	Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas［J］. Crit Rev Oncol Hematol, 2016, 99: 332-350. DOI: 10.1016/j.critrevonc.2016.01.012.
［20］	章雪飞, 吉春宇, 谷志涛, 等. 血清细胞角蛋白19片段与胸腺肿瘤临床病理特征和预后相关性研究［J］. 中国肺癌杂志, 2018, 21(7): 30-36. DOI: 10.3779/j.issn.1009-3419.2018.07.03.
［21］	Wang W, Liu D, Yang L, et al. CXCR4 overexpression correlates with poor prognosis in myasthenia gravis-associated thymoma［J］. Hum Pathol, 2016, 49: 49-53. DOI: 10.1016/j.humpath.2015.10.007.
［22］	史金胜, 刘美芹, 温静静, 等. 胸腺瘤STAT3表达临床意义分析［J］. 实用肿瘤杂志, 2019, 34(1): 27-30. DOI: 10.13267/j.cnki.syzlzz.2019.01.006.
［23］	Santoni G, Amantini C, Morelli MB, et al. High CTLA-4 expression correlates with poor prognosis in thymoma patients［J］. Oncotarget, 2018, 9(24): 16665-16677. DOI: 10.18632/oncotarget.24645.
［24］	Owen D, Chu B, Lehman AM, et al. Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma［J］. J Thorac Oncol, 2018, 13(8): 1204-1212. DOI: 10.1016/j.jtho.2018.04.013.
［25］	Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors［J］. J Thorac Dis, 2018, 10(Suppl 13): S1509-S1515. DOI: 10.21037/jtd.2017.10.157.
［26］	Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma［J］. Lung Cancer, 2015, 88(2): 154-159. DOI: 10.1016/j.lungcan.2015.03.003.
［27］	Yokoyama S, Miyoshi H, Nishi T, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma［J］. Ann Thorac Surg, 2016, 101(4): 1361-1369. DOI: 10.1016/j.athoracsur.2015.10.044.
［28］	Yokoyama S, Miyoshi H, Nakashima K, et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma［J］. Clin Cancer Res, 2016, 22(18): 4727-4734. DOI: 10.1158/1078-0432.Ccr-16-0434.
［29］	夏钰弘, 杨树东, 郭庆, 等. 胸腺瘤组织c-kit、pten表达变化及其与WHO分型、患者预后的关系［J］. 山东医药, 2018, 58(4): 86-88. DOI: 10.3969/j.issn.1002-266X.2018.04.030.
［30］	张宏毅. 胸腺瘤基因学突变特点［D］. 天津: 天津医科大学, 2017.
［31］	Gong J, Jin S, Pan X, et al. Identification of long noncoding RNAs for predicting prognosis among patients with thymoma［J］. Clin Lab, 2018, 64(7): 1193-1198. DOI: 10.7754/Clin.Lab.2018.180136.
［32］	Wei J, Liu Z, Wu K, et al. Identification of prognostic and subtype-specific potential mirnas in thymoma［J］. Epigenomics, 2017, 9(5): 647-657. DOI: 10.2217/epi-2016-0161.
［33］	Yang G, Zhang W, Yu C, et al. MicroRNA let-7: regulation, single nucleotide polymorphism, and therapy in lung cancer［J］. J Cancer Res Ther, 2015, 11 Suppl 1: C1-C6. DOI: 10.4103/0973-1482.163830.
［34］	Haakensen VD, Nygaard V, Greger L, et al. Subtype-specific micro-RNA expression signatures in breast cancer progression［J］. Int J Cancer, 2016, 139(5): 1117-1128. DOI: 10.1002/ijc.30142.
［35］	Li S, Yuan Y, Xiao H, et al. Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors［J］. Clin Epigenetics, 2019, 11(1): 38. DOI: 10.1186/s13148-019-0619-z.
［36］	Lee GJ, Lee H, Woo IS, et al. Erratum to “high expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors” ［Lung Cancer 132 (June) (2019) 9-16］［J］. Lung Cancer, 2019, 136: 160. DOI: 10.1016/j.lungcan.2019.07.012.
［37］	Feng Y, Lei Y, Wu X, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis［J］. Lung Cancer, 2017, 110: 48-52. DOI: 10.1016/j.lungcan.2017.05.020.
［38］	Muriana P, Carretta A, Ciriaco P, et al. Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma［J］. J Cardiothorac Surg, 2018, 13(1): 119. DOI: 10.1186/s13019-018-0805-7.
［39］	Yanagiya M, Nitadori JI, Nagayama K, et al. Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio for complete resection of thymoma［J］. Surg Today, 2018, 48(4): 422-430. DOI: 10.1007/s00595-017-1602-y.
［40］	Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients［J］. Br J Cancer, 2014, 110(1): 183-188. DOI: 10.1038/bjc.2013.701.
［41］	Janik S, Bekos C, Hacker P, et al. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: a pro- and retrospective analysis［J］. Oncotarget, 2017, 8(29): 47090-47102. DOI: 10.18632/oncotarget.17478.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.